272 related articles for article (PubMed ID: 28531175)
1. Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.
Azoulay E; Timsit JF; Lautrette A; Legriel S; Max A; Ruckly S; Misset B; Cohen Y; Wolff M
PLoS One; 2017; 12(5):e0177093. PubMed ID: 28531175
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.
Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J
Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784
[TBL] [Abstract][Full Text] [Related]
3. Biliary amphotericin B pharmacokinetics and pharmacodynamics in critically ill liver transplant recipients receiving treatment with amphotericin B lipid formulations.
Welte R; Eschertzhuber S; Weiler S; Leitner-Rupprich S; Aigner M; Lass-Flörl C; Stienecke E; Bellmann-Weiler R; Joannidis M; Bellmann R
Int J Antimicrob Agents; 2015 Sep; 46(3):325-31. PubMed ID: 26119497
[TBL] [Abstract][Full Text] [Related]
4. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
[TBL] [Abstract][Full Text] [Related]
5. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
[TBL] [Abstract][Full Text] [Related]
6. [Retrospective investigation on the cases treated with liposomal amphotericin B].
Yamagishi Y; Mikamo H
Jpn J Antibiot; 2010 Oct; 63(5):347-64. PubMed ID: 21268407
[TBL] [Abstract][Full Text] [Related]
7. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates.
Juster-Reicher A; Flidel-Rimon O; Amitay M; Even-Tov S; Shinwell E; Leibovitz E
Eur J Clin Microbiol Infect Dis; 2003 Oct; 22(10):603-7. PubMed ID: 13680398
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.
Wasan KM; Conklin JS
Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Andes D; Safdar N; Marchillo K; Conklin R
Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
[TBL] [Abstract][Full Text] [Related]
10. Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry.
Della Pepa R; Picardi M; Sorà F; Stamouli M; Busca A; Candoni A; Delia M; Fanci R; Perriello V; Zancanella M; Nosari A; Salutari P; Marchesi F; Pane F; Pagano L;
Support Care Cancer; 2016 Sep; 24(9):3839-45. PubMed ID: 27075673
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany.
Cornely OA; Sidhu M; Odeyemi I; van Engen AK; van der Waal JM; Schoeman O
Curr Med Res Opin; 2008 Jun; 24(6):1743-53. PubMed ID: 18477422
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.
Gubbins PO; Amsden JR; McConnell SA; Anaissie EJ
Antimicrob Agents Chemother; 2009 Sep; 53(9):3664-74. PubMed ID: 19546359
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia.
Noguchi S; Takahashi N; Ito M; Teshima K; Yamashita T; Michishita Y; Ohyagi H; Shida S; Nagao T; Fujishima M; Ikeda S; Ito I; Fujishima N; Kameoka Y; Saitoh H; Tagawa H; Hirokawa M; Sawada K
Int J Clin Oncol; 2013 Dec; 18(6):983-7. PubMed ID: 23076821
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of liposomal amphotericin B in patients admitted to the ICU on renal replacement therapy.
Álvarez-Lerma F; Rodriguez M; Soriano MC; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maravi E; Fernández Rey E; Alvarado F; López-Sánchez M; Alvarez-Sánchez B; Granado D; Quintana E;
Rev Esp Quimioter; 2013 Dec; 26(4):360-8. PubMed ID: 24399350
[TBL] [Abstract][Full Text] [Related]
15. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
Timsit JF; Azoulay E; Schwebel C; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Argaud L; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Maubon D; Jullien V; Wolff M;
JAMA; 2016 Oct; 316(15):1555-1564. PubMed ID: 27706483
[TBL] [Abstract][Full Text] [Related]
16. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
[TBL] [Abstract][Full Text] [Related]
17. Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.
Chong GL; Broekman F; Polinder S; Doorduijn JK; Lugtenburg PJ; Verbon A; Cornelissen JJ; Rijnders BJ
Int J Antimicrob Agents; 2015 Jul; 46(1):82-7. PubMed ID: 25956843
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of pulsed high-dose L-AmB as pre-emptive therapy in patients at high risk for intra-abdominal candidiasis: A phase 2 study (LAMBDA study).
Rinaldi M; Bartoletti M; Bonazzetti C; Caroccia N; Gatti M; Tazza B; Horna CS; Giannella M; Viale P
Int J Antimicrob Agents; 2023 Dec; 62(6):106998. PubMed ID: 37838147
[TBL] [Abstract][Full Text] [Related]
19. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis.
Bae JH; Lee SC
Jpn J Ophthalmol; 2015 Sep; 59(5):346-52. PubMed ID: 26215152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
